Maven Securities LTD Invests $866,000 in SOPHiA GENETICS SA $SOPH

Key Points

• Maven Securities acquired 150,000 SOPHiA GENETICS shares worth approximately $866,000 in the second quarter, representing about 0.18% of the company; institutional investors overall own 31.59%.
• Analyst sentiment is mixed but improved recently: HC Wainwright and BTIG raised their price targets and reiterated Buy ratings, while the consensus rating remains Hold with an average target of $10.00.
• SOPHiA GENETICS reported quarterly revenue of $23.31 million, above estimates, but its $0.26 loss per share missed expectations. Insiders have sold 336,342 shares worth roughly $2.15 million over the past three months.

Maven Securities LTD acquired a new stake in shares of SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 150,000 shares of the company's stock, valued at approximately $866,000. Maven Securities LTD owned about 0.18% of SOPHiA GENETICS at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SOPH. Perkins Capital Management Inc. acquired a new position in SOPHiA GENETICS in the 4th quarter worth about $49,000. Squarepoint Ops LLC acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter valued at about $49,000. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at approximately $50,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS in the fourth quarter worth approximately $54,000. Finally, XTX Topco Ltd acquired a new position in SOPHiA GENETICS in the fourth quarter worth approximately $55,000. Hedge funds and other institutional investors own 31.59% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on SOPH. HC Wainwright raised their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Wednesday, August 5th. BTIG Research boosted their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of "Hold" and an average price target of $10.00.

Insider Transactions at SOPHiA GENETICS

In other news, Director Kathy L. Hibbs sold 6,250 shares of the stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $8.68, for a total value of $54,250.00. Following the completion of the sale, the director directly owned 103,242 shares of the company's stock, valued at approximately $896,140.56. This represents a 5.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 5,000 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $8.80, for a total value of $44,000.00. Following the completion of the sale, the chief technology officer directly owned 172,171 shares of the company's stock, valued at $1,515,104.80. This represents a 2.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 336,342 shares of company stock worth $2,154,775. Insiders own 4.88% of the company's stock.

SOPHiA GENETICS Stock Up 3.3%

SOPH stock opened at $8.36 on Wednesday. The stock has a market capitalization of $701.36 million, a price-to-earnings ratio of -7.27 and a beta of 0.98. The company has a 50-day moving average of $6.89 and a two-hundred day moving average of $5.63. SOPHiA GENETICS SA has a 52-week low of $3.10 and a 52-week high of $8.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. As a group, equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

Want to see what other hedge funds are holding SOPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SOPHiA GENETICS SA (NASDAQ:SOPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.